Myelodysplastic Syndromes (MDS)

Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes

Original Publication Date

April 11, 2025

Article Source

External Web Content

Abstract Dissecting the preneoplastic disease states’ biological mechanisms that precede tumorigenesis can lead to interventions that can slow down disease progression and/or mitigate disease-related comorbidities. Myelodysplastic syndromes (MDS) cannot be cured by currently…

2025 Boston Patient and Family Conference

Read more about 2025 Boston Patient and Family Conference

Session Recordings Available:

2025 Chapel Hill Patient and Family Conference

Read more about 2025 Chapel Hill Patient and Family Conference

Recordings:

Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry

Read more about Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry

Infections are an important cause of morbidity and mortality in patients with lower-risk myelodysplastic syndromes myelodysplastic syndromes:

Transplant and GVHD Session - 2025 Kansas City Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

Bone Marrow Transplant

In this recording, Dr. Anurag Singh discusses transplant and potentials complications such as GVHD and treatment options. Recording includes the question-and-answer session.

Living Well with Bone Marrow Failure, from the 2025 Kansas City Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

Living Well with Bone Marrow Failure

Managing Your Treatment

In this recording, Dr. Furha Cossor discusses living with bone marrow failure and fatigue management. Recording includes the question-and-answer session.

Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study

Read more about Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study

Hypomethylating agents (HMA) are indicated in the treatment of higher-risk myelodysplastic syndromes myelodysplastic syndromes:

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Read more about Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

Read more about Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms

Read more about Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms

Context.—: Standardized bone marrow bone marrow: The soft, spongy tissue inside most bones.

Subscribe to Myelodysplastic Syndromes (MDS)